Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Sudan Ebolavirus VP35-NP Crystal Structure Reveals a Potential Target for Pan-Filovirus Treatment.

Landeras-Bueno S, Oda SI, Norris MJ, Li Salie Z, Guenaga J, Wyatt RT, Saphire EO.

MBio. 2019 Jul 23;10(4). pii: e00734-19. doi: 10.1128/mBio.00734-19.

2.

Differential processing of HIV envelope glycans on the virus and soluble recombinant trimer.

Cao L, Pauthner M, Andrabi R, Rantalainen K, Berndsen Z, Diedrich JK, Menis S, Sok D, Bastidas R, Park SR, Delahunty CM, He L, Guenaga J, Wyatt RT, Schief WR, Ward AB, Yates JR 3rd, Burton DR, Paulson JC.

Nat Commun. 2018 Sep 12;9(1):3693. doi: 10.1038/s41467-018-06121-4.

3.

Phosphoserine acidic cluster motifs bind distinct basic regions on the μ subunits of clathrin adaptor protein complexes.

Singh R, Stoneham C, Lim C, Jia X, Guenaga J, Wyatt R, Wertheim JO, Xiong Y, Guatelli J.

J Biol Chem. 2018 Oct 5;293(40):15678-15690. doi: 10.1074/jbc.RA118.003080. Epub 2018 Aug 22.

4.

Structure-Guided Redesign Improves NFL HIV Env Trimer Integrity and Identifies an Inter-Protomer Disulfide Permitting Post-Expression Cleavage.

Yang L, Sharma SK, Cottrell C, Guenaga J, Tran K, Wilson R, Behrens AJ, Crispin M, de Val N, Wyatt RT.

Front Immunol. 2018 Jul 17;9:1631. doi: 10.3389/fimmu.2018.01631. eCollection 2018.

5.

Ligand accessibility to the HIV-1 Env co-receptor binding site can occur prior to CD4 engagement and is independent of viral tier category.

Boliar S, Patil S, Shukla BN, Ghobbeh A, Deshpande S, Chen W, Guenaga J, Dimitrov DS, Wyatt RT, Chakrabarti BK.

Virology. 2018 Jun;519:99-105. doi: 10.1016/j.virol.2018.04.002. Epub 2018 May 11.

6.

Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity.

Steinhardt JJ, Guenaga J, Turner HL, McKee K, Louder MK, O'Dell S, Chiang CI, Lei L, Galkin A, Andrianov AK, A Doria-Rose N, Bailer RT, Ward AB, Mascola JR, Li Y.

Nat Commun. 2018 Feb 28;9(1):877. doi: 10.1038/s41467-018-03335-4.

7.

Glutaraldehyde Cross-linking of HIV-1 Env Trimers Skews the Antibody Subclass Response in Mice.

Soldemo M, Àdori M, Stark JM, Feng Y, Tran K, Wilson R, Yang L, Guenaga J, Wyatt RT, Karlsson Hedestam GB.

Front Immunol. 2017 Nov 27;8:1654. doi: 10.3389/fimmu.2017.01654. eCollection 2017.

8.

Targeted N-glycan deletion at the receptor-binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody response.

Dubrovskaya V, Guenaga J, de Val N, Wilson R, Feng Y, Movsesyan A, Karlsson Hedestam GB, Ward AB, Wyatt RT.

PLoS Pathog. 2017 Sep 13;13(9):e1006614. doi: 10.1371/journal.ppat.1006614. eCollection 2017 Sep.

9.

HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.

Wang Y, O'Dell S, Turner HL, Chiang CI, Lei L, Guenaga J, Wilson R, Martinez-Murillo P, Doria-Rose N, Ward AB, Mascola JR, Wyatt RT, Karlsson Hedestam GB, Li Y.

J Virol. 2017 Oct 13;91(21). pii: e00910-17. doi: 10.1128/JVI.00910-17. Print 2017 Nov 1.

10.

Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches.

Pauthner M, Havenar-Daughton C, Sok D, Nkolola JP, Bastidas R, Boopathy AV, Carnathan DG, Chandrashekar A, Cirelli KM, Cottrell CA, Eroshkin AM, Guenaga J, Kaushik K, Kulp DW, Liu J, McCoy LE, Oom AL, Ozorowski G, Post KW, Sharma SK, Steichen JM, de Taeye SW, Tokatlian T, Torrents de la Peña A, Butera ST, LaBranche CC, Montefiori DC, Silvestri G, Wilson IA, Irvine DJ, Sanders RW, Schief WR, Ward AB, Wyatt RT, Barouch DH, Crotty S, Burton DR.

Immunity. 2017 Jun 20;46(6):1073-1088.e6. doi: 10.1016/j.immuni.2017.05.007.

11.

Particulate Array of Well-Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach.

Martinez-Murillo P, Tran K, Guenaga J, Lindgren G, Àdori M, Feng Y, Phad GE, Vázquez Bernat N, Bale S, Ingale J, Dubrovskaya V, O'Dell S, Pramanik L, Spångberg M, Corcoran M, Loré K, Mascola JR, Wyatt RT, Karlsson Hedestam GB.

Immunity. 2017 May 16;46(5):804-817.e7. doi: 10.1016/j.immuni.2017.04.021.

12.

Glycine Substitution at Helix-to-Coil Transitions Facilitates the Structural Determination of a Stabilized Subtype C HIV Envelope Glycoprotein.

Guenaga J, Garces F, de Val N, Stanfield RL, Dubrovskaya V, Higgins B, Carrette B, Ward AB, Wilson IA, Wyatt RT.

Immunity. 2017 May 16;46(5):792-803.e3. doi: 10.1016/j.immuni.2017.04.014.

13.

Synthetic multivalent V3 glycopeptides display enhanced recognition by glycan-dependent HIV-1 broadly neutralizing antibodies.

Cai H, Orwenyo J, Guenaga J, Giddens J, Toonstra C, Wyatt RT, Wang LX.

Chem Commun (Camb). 2017 May 14;53(39):5453-5456. doi: 10.1039/c7cc02059g. Epub 2017 May 3.

14.

Global site-specific N-glycosylation analysis of HIV envelope glycoprotein.

Cao L, Diedrich JK, Kulp DW, Pauthner M, He L, Park SR, Sok D, Su CY, Delahunty CM, Menis S, Andrabi R, Guenaga J, Georgeson E, Kubitz M, Adachi Y, Burton DR, Schief WR, Yates JR III, Paulson JC.

Nat Commun. 2017 Mar 28;8:14954. doi: 10.1038/ncomms14954.

15.

Evolution of B cell analysis and Env trimer redesign.

Karlsson Hedestam GB, Guenaga J, Corcoran M, Wyatt RT.

Immunol Rev. 2017 Jan;275(1):183-202. doi: 10.1111/imr.12515. Review.

16.

An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes.

Chen Y, Wilson R, O'Dell S, Guenaga J, Feng Y, Tran K, Chiang CI, Arendt HE, DeStefano J, Mascola JR, Wyatt RT, Li Y.

J Immunol. 2016 Nov 15;197(10):3982-3998. Epub 2016 Oct 10.

17.

Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding.

Longo NS, Sutton MS, Shiakolas AR, Guenaga J, Jarosinski MC, Georgiev IS, McKee K, Bailer RT, Louder MK, O'Dell S, Connors M, Wyatt RT, Mascola JR, Doria-Rose NA.

J Virol. 2016 Nov 14;90(23):10574-10586. doi: 10.1128/JVI.01012-16. Print 2016 Dec 1.

18.

Thermostability of Well-Ordered HIV Spikes Correlates with the Elicitation of Autologous Tier 2 Neutralizing Antibodies.

Feng Y, Tran K, Bale S, Kumar S, Guenaga J, Wilson R, de Val N, Arendt H, DeStefano J, Ward AB, Wyatt RT.

PLoS Pathog. 2016 Aug 3;12(8):e1005767. doi: 10.1371/journal.ppat.1005767. eCollection 2016 Aug.

19.

High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells.

Ingale J, Stano A, Guenaga J, Sharma SK, Nemazee D, Zwick MB, Wyatt RT.

Cell Rep. 2016 May 31;15(9):1986-99. doi: 10.1016/j.celrep.2016.04.078. Epub 2016 May 19.

20.

HIV-1 Vaccine-elicited Antibodies Reverted to Their Inferred Naive Germline Reveal Associations between Binding Affinity and in vivo Activation.

Dai K, Khan SN, Wang Y, He L, Guenaga J, Ingale J, Sundling C, O'Dell S, McKee K, Phad G, Corcoran M, Wilson R, Mascola JR, Zhu J, Li Y, Karlsson Hedestam GB, Wyatt RT.

Sci Rep. 2016 Feb 16;6:20987. doi: 10.1038/srep20987.

21.

Structure-Guided Redesign Increases the Propensity of HIV Env To Generate Highly Stable Soluble Trimers.

Guenaga J, Dubrovskaya V, de Val N, Sharma SK, Carrette B, Ward AB, Wyatt RT.

J Virol. 2015 Dec 30;90(6):2806-17. doi: 10.1128/JVI.02652-15.

22.

Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design.

Sharma SK, de Val N, Bale S, Guenaga J, Tran K, Feng Y, Dubrovskaya V, Ward AB, Wyatt RT.

Cell Rep. 2015 Apr 28;11(4):539-50. doi: 10.1016/j.celrep.2015.03.047. Epub 2015 Apr 16.

23.

Well-ordered trimeric HIV-1 subtype B and C soluble spike mimetics generated by negative selection display native-like properties.

Guenaga J, de Val N, Tran K, Feng Y, Satchwell K, Ward AB, Wyatt RT.

PLoS Pathog. 2015 Jan 8;11(1):e1004570. doi: 10.1371/journal.ppat.1004570. eCollection 2015 Jan.

24.

HIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunization.

Navis M, Tran K, Bale S, Phad GE, Guenaga J, Wilson R, Soldemo M, McKee K, Sundling C, Mascola J, Li Y, Wyatt RT, Karlsson Hedestam GB.

PLoS Pathog. 2014 Aug 28;10(8):e1004337. doi: 10.1371/journal.ppat.1004337. eCollection 2014 Aug.

25.

Computational design of protein antigens that interact with the CDR H3 loop of HIV broadly neutralizing antibody 2F5.

Azoitei ML, Ban YA, Kalyuzhny O, Guenaga J, Schroeter A, Porter J, Wyatt R, Schief WR.

Proteins. 2014 Oct;82(10):2770-82. doi: 10.1002/prot.24641. Epub 2014 Jul 31.

26.

Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign.

Tran K, Poulsen C, Guenaga J, de Val N, Wilson R, Sundling C, Li Y, Stanfield RL, Wilson IA, Ward AB, Karlsson Hedestam GB, Wyatt RT.

Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):E738-47. doi: 10.1073/pnas.1319512111. Epub 2014 Feb 3. Erratum in: Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):E1159. Proc Natl Acad Sci U S A. 2014 Feb 18;111(7). doi:10.1073/pnas.1403776111. de Val Alda, Natalia [corrected to de Val, Natalia].

27.

Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41.

Zhang MY, Yuan T, Li J, Rosa Borges A, Watkins JD, Guenaga J, Yang Z, Wang Y, Wilson R, Li Y, Polonis VR, Pincus SH, Ruprecht RM, Dimitrov DS.

PLoS One. 2012;7(9):e44241. doi: 10.1371/journal.pone.0044241. Epub 2012 Sep 10.

28.

HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins.

Li Y, O'Dell S, Wilson R, Wu X, Schmidt SD, Hogerkorp CM, Louder MK, Longo NS, Poulsen C, Guenaga J, Chakrabarti BK, Doria-Rose N, Roederer M, Connors M, Mascola JR, Wyatt RT.

J Virol. 2012 Oct;86(20):11231-41. Epub 2012 Aug 8.

29.

Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function.

Guenaga J, Wyatt RT.

PLoS Pathog. 2012;8(7):e1002806. doi: 10.1371/journal.ppat.1002806. Epub 2012 Jul 19.

30.

Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01.

Li Y, O'Dell S, Walker LM, Wu X, Guenaga J, Feng Y, Schmidt SD, McKee K, Louder MK, Ledgerwood JE, Graham BS, Haynes BF, Burton DR, Wyatt RT, Mascola JR.

J Virol. 2011 Sep;85(17):8954-67. doi: 10.1128/JVI.00754-11. Epub 2011 Jun 29.

31.

Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity.

Chakrabarti BK, Walker LM, Guenaga JF, Ghobbeh A, Poignard P, Burton DR, Wyatt RT.

J Virol. 2011 Aug;85(16):8217-26. doi: 10.1128/JVI.00756-11. Epub 2011 Jun 8.

32.

Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant.

Guenaga J, Dosenovic P, Ofek G, Baker D, Schief WR, Kwong PD, Karlsson Hedestam GB, Wyatt RT.

PLoS One. 2011 Jan 26;6(1):e16074. doi: 10.1371/journal.pone.0016074.

33.

HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.

Chakrabarti BK, Pancera M, Phogat S, O'Dell S, McKee K, Guenaga J, Robinson J, Mascola J, Wyatt RT.

AIDS Res Hum Retroviruses. 2011 Aug;27(8):877-87. doi: 10.1089/AID.2010.0281. Epub 2011 Jan 19.

34.

Variability of indication criteria in knee and hip replacement: an observational study.

Cobos R, Latorre A, Aizpuru F, Guenaga JI, Sarasqueta C, Escobar A, García L, Herrera-Espiñeira C.

BMC Musculoskelet Disord. 2010 Oct 26;11:249. doi: 10.1186/1471-2474-11-249.

35.

Evaluation of the pathogenesis of decreasing CD4(+) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretroviral therapy.

Nies-Kraske E, Schacker TW, Condoluci D, Orenstein J, Brenchley J, Fox C, Daucher M, Dewar R, Urban E, Hill B, Guenaga J, Hoover S, Maldarelli F, Hallahan CW, Horn J, Kottilil S, Chun TW, Folino M, Palmer S, Wiegand A, O'Shea MA, Metcalf JA, Douek DC, Coffin J, Haase A, Fauci AS, Dybul M.

J Infect Dis. 2009 Jun 1;199(11):1648-56. doi: 10.1086/598980.

36.

Development of explicit criteria for prioritization of hip and knee replacement.

Escobar A, Quintana JM, Bilbao A, Ibañez B, Arenaza JC, Gutiérrez L, Azkárate J, Güenaga JI, Vidaurreta I.

J Eval Clin Pract. 2007 Jun;13(3):429-34.

PMID:
17518810
37.

Effect of patient characteristics on reported outcomes after total knee replacement.

Escobar A, Quintana JM, Bilbao A, Azkárate J, Güenaga JI, Arenaza JC, Gutierrez LF.

Rheumatology (Oxford). 2007 Jan;46(1):112-9. Epub 2006 May 30.

PMID:
16735451
38.

Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia.

Haining WN, Neuberg DS, Keczkemethy HL, Evans JW, Rivoli S, Gelman R, Rosenblatt HM, Shearer WT, Guenaga J, Douek DC, Silverman LB, Sallan SE, Guinan EC, Nadler LM.

Blood. 2005 Sep 1;106(5):1749-54. Epub 2005 May 26.

39.

Development of explicit criteria for total knee replacement.

Escobar A, Quintana JM, Aróstegui I, Azkárate J, Güenaga JI, Arenaza JC, Garai I.

Int J Technol Assess Health Care. 2003 Winter;19(1):57-70.

PMID:
12701939
40.
41.

[Appropriate use of the mechanisms for the fixation of hip prostheses].

Escobar A, Quintana JM, Aróstegul I, Azkárate J, Güenaga JI.

Gac Sanit. 2000 Sep-Oct;14(5):371-7. Spanish.

Supplemental Content

Loading ...
Support Center